However, it was recently reported that mTORC1 activation may suppress tumorigenesis in patients with inflammatory bowel disease who develop CRC via chromosomal aberrations and IL‐6‐associated inflammation blocking, but may promote CRC oncogenesis in patients with APC mutations, which demonstrates the oncogenic and tumor‐suppressive roles of mTORC1 in tumorigenesis.33 Thus, mTORC1 may execute completely different functions in tumors with a different pathogenesis. This evidence concerns the gene IL6 and neoplasm.